Is Relapse Rate Reduced by Home Monitoring of IBD Patients Tightly or on Demand by FC and Disease Activity?
The purpose of this study is to determine if the IBD patient doing home monitoring by web app's for disease activity (DA) and fecal calprotectin (FC) on demand (OD), compared with patients doing home monitoring scheduled interval combined with "on demand"(SI+OD) ( every 3.month).
Will home monitoring of DA and FC OD vs SI+OD reduce frequency of relapse in one year follow up? Is the frequent FC measurement in SI+OD test group predictive of an early recognition of relapse, and thus help change the naturel course of disease? Will home monitoring of DA and FC in OD vs SI+OD change the course of the disease in terms of disease activity, spread of the disease, hospitalizations and number of hospitalization days, required surgery and outpatient visits? Is there a difference in patients' compliance with treatment plan between OD vs SI+OD ? Is there difference in patients-adherence between OD vs SI+OD ?
調査の概要
詳細な説明
Detailed Description Among 2.500 IBD patients the investigators will consecutively from the Gastroenterology out-patient clinic at North Zealand University Hospital recruit in total 120 in the study.
At the out-patient consultation IBD patients will be informed about the project and the IBD eHealth nurse ensures that no exclusion criteria met by the patient.
Inclusion criteria: IBD patients in remission, SCCAI ≤ 2 (Simple Clinical Colitis Activity Index )) or HBI < 5 (Harvey & Bradshaw Activity Index ) or in mild to moderate disease activity ( SCCAI 3-4, HBI < 16) IBD patients who can read, speak and understand Danish IBD patients that can take advantage of the Internet and wireless network 18years or older.
Exclusion criteria: IBD patients with severe disease activity HB > 16 SCCAI ≥ 5 ) IBD patients with social, medical or psychological issues of a more complex character IBD patients with particularly complex issues such as drug and alcohol problems, severe mental / psychiatric disorders and / or serious social impact.
IBD patients who cannot attend due language barrier or cognitive disorder. Age less 18. When the patient has agreed to participate in the study, randomized to either OD or SI OD 3. Months (SI group):
Patients log in at www.noh.constant-care.dk at least once every 3rd months throughout the project period of 12 months. When the patient log in to the telemedicine platform following scoring must be filled out:
- - Disease activity, respectively SCCAI or HBI.
- - Quality of life assessment, in s - IBDQ every 3rd months.
- - FACIT (Fatigue score)
- MARS ( Medical Adherence Rating Scale)
- FC, fecal calprotectin mg / kg feces) with SMART phone, rapid home test. If the patients prefer to send the feces test, it will be tested in the Gastro unit lab. at the hospital with SMART phone.
The results of the scoring systems will appear to the health professionals and patients in a traffic light turning into red, yellow and green.
If the patient experiences a recurrence of the disease, it moves from green to either yellow or red area in the traffic graph, and patient will further be instructed to contact Gastro medical clinic project nurse for an early consultation and decision on further treatment initiative. This will also be indicated at the patient's website. If alarm symptoms occurs patients are instructed to contact the project nurse. Thus patients are treated in accordance to national and international guideline. By screening of the inflammation burden the decision is moving forward.
On Demand Group:
Patients log in on demand,detects disease activity, quality of life and FC at the start, and subsequently when needed and at the end of the study (12 months).
At relapse disease activity score and FC is settled and repeated no later than 7 days here after at remission a new DA and FC test should be performed to verify the remission.
Statistical considerations:
Randomization Suitable (N = 120) will be randomized to one of the test groups by sealed envelope principle.
Material size calculation:
A relapse last in median 18 days in patients with inflammatory bowel disease, but the variance is large (10-50 days). During one year of a prevalent IBD patient group 50 % of a patient population will experience a relapse. To assess whether fewer patients experience true "red" indicated by relapse via (TIBS) Feces Calprotectin (FC ) and disease activity in group 1 vs. Group 2 respectively, the sample size has been depicted from TIBS and a statistically significance ( α ) of 0.05 , and test force of ( β ) of 0.8 .
This means that there must be included 53 individuals in each group, which means that there must be included a total of 106. Thus the investigators have chosen to include 120 patients, 60 in each group in order to correct for a possible of small drop out in each group.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Capital Region
-
Frederikssund、Capital Region、デンマーク、3600
- North Zealands Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- IBD patients in remission, SCCAI ≤ 2 (Simple Clinical Colitis Activity Index )) or HBI < 5 (Harvey & Bradshaw Activity Index ) or in mild to moderate disease activity ( SCCAI 3-4, HBI < 16)
- IBD patients who can read, speak and understand Danish
- IBD patients that can take advantage of the Internet and wireless network 18 years or older
Exclusion Criteria:
- IBD patients with severe disease activity ( HB > 16 SCCAI ≥ 5 )
- IBD patients with social, medical or psychological issues of a more complex character
- IBD patients with particularly complex issues such as drug and alcohol problems, severe mental / psychiatric disorders and / or serious social impact.
- IBD patients who cannot attend due language barrier or cognitive disorder.
- Age less 18.
- When the patient has agreed to participate in the study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ヘルスサービス研究
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Scheduled (SI)
"Scheduled" means screening every 3rd month ( home FC and DA) plus when needed and upgrade of ususal treatment
|
A routine scheduled (SI) screening of FC and DA every 3rd month
|
|
アクティブコンパレータ:On Demand (OD)
On "Demand" means screening of home FC and DA when the patients feel for it and upgrade of usual treatment
|
A screening of FC and DA on demand (OD)
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Total Inflammation Burden Scoring ( TIBS)
時間枠:1 year
|
The outcome measure of TIBS (FC ( ELISA Smartphone test)and Disease Activity ( Simple Clical Colitis Activity Index or Harvey-Bradshaw Index) has been chosen as endpoint for comparing the two screening methods in relation to relapse rate
|
1 year
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。